Osteoporosis is a very common disease that occurs among patients who have irregular density of bone minerals that results in unhealthy changes in bone microstructures, a higher risk of fragile bones, and consequently fractures. The condition can be observed most commonly in the spine, shoulders hips, and arms, and anti-osteoporosis therapy is a defense against it that many prefer.
Fractures in the hip region occur with a relatively high frequency. In addition, approximately a third of such patients suffer from lower mobility and require nursing services for a longer period of time. As such patients find it extremely difficult to move, prolonged bed rest can even lead to extreme pain and complications that can sometimes result in death.
In such a situation, growing importance of osteoporosis diagnostic procedures including X-rays, bone density tests, and radiography are gaining importance in the anti-osteoporosis and fracture healing therapy market, as they effectively can raise bone mineral density and reduce rate of bone tissue loss, much faster than conventional means.
More Read
Combining Exercise and Anti-Osteoporotic Medication Will Gain Prominence
Osteoporosis is relatively more common among elderly women in comparison to men. Anti-osteoporosis therapies are seeing increasing use to boost the density of bone minerals while simultaneously keeping control over the reduction of overall bone tissue. Anti-osteoporosis therapies lessen the risk of fractures especially among geriatrics.
As per a recent report by Future Market Insights on the anti-osteoporosis and fracture healing market a high rate of annual growth is expected in the years to come. This can be attributed to rising incidences of osteoporosis in patients and growing number of bone disease cases that are arising from unhealthy sedentary lifestyles that are boosting the growth of demand worldwide. As a result, therapeutic workouts are often being combined with anti-osteoporosis anabolic medication to achieve optimal results.
Moreover, rising amounts of investments in research in the development of new drugs and increasing osteoporosis awareness among health care professionals and patients are also creating a requirement for newer osteoporosis treatments.
Shorter Durations of Treatment to Boost Demand for Fracture Healing Therapy
On the other hand, aspects such as risk of complications and the various types of side effects including irritable bowel syndrome, nausea, symptoms of influenza, and ulcers arising the use of such therapies are challenges that must be addressed by producers.
Major medication manufacturers for anti-osteoporosis therapies worldwide such as Actavis plc, Eli Lilly and Company, Merck and Company Inc., Teva Pharmaceutical Industries Ltd., , Amgen Inc., F.Hoffmann La Roche Ltd., Novartis International AG., Pfizer, Inc., and GlaxoSmithKline plc, are putting massive focus on R&D and expansion strategies to gain competitive advantages.
Overall, the worldwide demand for anti-osteoporosis and fracture healing therapy will grow rapidly at a higher rate owing to high efficiency of such treatments, and shorter recovery times afforded to patients among other enhanced benefits over conventional osteoporosis therapies.
Oral and injectable medications for osteoporosis including bases of biophosphonates, ibandronate, and selective oestrogen receptor modulators (SERM) among others enable such benefits, and will generate higher demand in the long run.
Final Thoughts
North America and Europe will generate significantly higher demand for anti-osteoporosis global therapies in the near future owing to boosted investment in R&D for the development of new drugs, a rapidly expanding population of the elderly and growing rates of related health issues that are associated to unhealthy lifestyles and diets.
Developing nations such as India, Brazil, and China are also estimated to give very high rates of growth of the demand for anti-osteoporosis therapy and fracture healing procedures, owing to affordable medical facilities and increasing popularity of medical tourism in these countries.
